The mixed-lineage leukemia (MLL) gene encodes a protein with homology to Drosophila trithorax (TRX) 1 . MLL and TRX belong to an evolutionarily conserved family of proteins that positively regulate gene expression during development 2, 3 . These proteins counteract the effect of Polycomb family proteins, which maintain the inactive state of target genes 4, 5 . Combined chromatin immunoprecipitation and microarray (ChIP-on-chip) experiments indicate that MLL is associated with over 5,000 human promoters, suggesting that MLL may have a global role in transcription 6 . The best-studied downstream targets of MLL are homeobox (Hox) genes 3,7 . MLL is required for the maintenance of spatial patterns of Hox gene expression during development and hematopoiesis 3, 8, 9 .
a r t i c l e s
The mixed-lineage leukemia (MLL) gene encodes a protein with homology to Drosophila trithorax (TRX) 1 . MLL and TRX belong to an evolutionarily conserved family of proteins that positively regulate gene expression during development 2, 3 . These proteins counteract the effect of Polycomb family proteins, which maintain the inactive state of target genes 4, 5 . Combined chromatin immunoprecipitation and microarray (ChIP-on-chip) experiments indicate that MLL is associated with over 5,000 human promoters, suggesting that MLL may have a global role in transcription 6 . The best-studied downstream targets of MLL are homeobox (Hox) genes 3, 7 . MLL is required for the maintenance of spatial patterns of Hox gene expression during development and hematopoiesis 3, 8, 9 .
MLL is a common target of chromosomal translocations found in human leukemias affecting both children 10 and adults 11 . MLL leukemia accounts for up to 10% of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in general. Translocations of MLL fuse an N-terminal fragment of MLL to 1 of more than 60 different fusion partners 9 . Regardless of the fusion partner, the presence of MLL translocations is associated with early relapse and poor prognosis 12 . In all MLL translocations, ~1,400 residues from the N terminus of MLL are fused in frame with the C terminus of the fusion partner 13 . Disruption of MLL by gene fusions upregulates expression of a subset of Hox genes, leading to a block in hematopoietic differentiation 9, 14 . Despite the heterogeneity of fusion partners, the portion of MLL retained is very similar and includes two regions that have been shown to be indispensable for leukemogenic transformation: the N-terminal region, which binds to menin and lens epithelium-derived growth factor (LEDGF) 15, 16 , and the conserved CXXC domain, which mediates binding to nonmethylated CpG motifs and the co-repressor proteins histone deacetylase 1 (HDAC1), Bmi1 polycomb ring-finger oncogene (Bmi1) and C-terminal binding protein (CtBP) (refs. 17-19) .
MLL-related leukemias are associated with upregulation of Hox genes, including Hoxa9 and Meis1 (ref. 14) . We have shown recently that MLL and the MLL-AF4 fusion protein bind to Hoxa9, protecting a specific cluster of CpGs within a CpG island from methylation and thereby maintaining expression of Hoxa9 locus transcripts 20 . The pattern of methylation of CpG islands differs between cell types, and an abnormal methylation pattern is frequently associated with various diseases, including multiple types of cancer 21 . Methylated CpG dinucleotides are recognized by the well-characterized methyl-binding domain (MBD) proteins 22 . To date, the only characterized domain capable of selective binding to unmethylated CpG dinucleotides is the CXXC domain. The CXXC domains from several proteins, including MLL 17, 18 , MBD1 (ref. 23 ) and CpG-binding protein (CGBP) 24 , have been shown to bind DNA and recognize unmethylated CpG dinucleotides. Functionally, both CXXC and MBD domains in concert play a key role in decoding the methylation status of CpG islands and interpreting cytosine methylation, ultimately leading to gene transcription or silencing.
To gain further insight into the mechanism of methylation protection by MLL and to assess the importance of this function for MLL fusion leukemia, we solved the structure of the human MLL CXXC domain in complex with DNA using solution NMR spectroscopy.
On the basis of the structure, we identified point mutations in the CXXC domain which abrogated DNA binding to various extents without perturbing the structure. We introduced these mutations into MLL-AF9 and found that loss of DNA binding by the CXXC domain was correlated with increased methylation at the Hoxa9 locus. Notably, introduction of these mutations into MLL-AF9 resulted in failure to immortalize primary bone marrow progenitor cells and failure to induce leukemia in mice. Our data provide new insights into the mechanism of transcriptional maintenance by MLL and MLL fusion proteins and provide support for the possible therapeutic utility of targeting the MLL CXXC-DNA interaction.
RESULTS

DNA-binding specificity of the MLL CXXC domain
Recently, we have shown that the CXXC domain of MLL binds DNA oligonucleotides derived from a CpG island in the Hoxa9 locus 20 . To determine whether the CXXC domain specifically recognizes DNA bases outside the core CpG motif, we tested binding to several designed oligonucleotides using isothermal titration calorimetry (ITC). These data (Supplementary Table 1) , as well as our recently published results 20 , suggest that the CXXC domain does not recognize DNA bases beyond the CpG dinucleotide and therefore is not solely responsible for specific localization to the Hoxa9 locus. This result is similar to that from a selected and amplified binding (SAAB) analysis of the binding specificity of the CGBP CXXC domain, which was also selective for a CpG motif but showed some selectivity for the flanking bases 24 . Notably, we observed 2-to 4-fold higher affinity for sites with multiple CpG motifs (Supplementary Table 1) , possibly indicative of one-dimensional diffusion along the DNA.
Structure of the CXXC domain in complex with CpG DNA We determined the structure of the human MLL CXXC domain in complex with DNA using NMR spectroscopy. We designed a palindromic dodecameric oligonucleotide (DNA pal ) with a central CpG dinucleotide and prepared an equimolar complex with 13 C, 15 N-labeled CXXC domain. To determine the structure of the complex, we measured an extensive set of experimental restraints, including intraand intermolecular distances and residual dipolar couplings (RDCs) (see Table 1 ).
Examination of the DNA spectra indicated the presence of two sets of resonances for the central 6-base-pair (bp) region of the palindromic oligonucleotide, consistent with the loss of symmetry of the DNA upon protein binding. We also observed exchange crosspeaks between the two complementary DNA strands arising from the reversal of the orientation of the bound CXXC domain. A similar phenomenon has been observed for the binding of methylated CpG DNA to MBD1 (refs. 22,25) . Although a virtually complete assignment of DNA resonances was obtained, broadening caused by the exchange process made the quantitative analysis of NOESY spectra and de novo calculation of the DNA structure intractable. Notably, the pattern of the NOEs observed for the DNA was very similar between free DNA and that in the complex (such as sequential NOEs involving base H6/H8 protons and deoxyribose H1′ protons). We also observed relatively modest chemical-shift changes for DNA upon protein binding (see Supplementary Table 2 ). The most significant chemicalshift changes (more than 0.2 p.p.m.) were observed only for protons that were in direct contact with the CXXC domain. These findings led us to conclude that the DNA conformation is not perturbed by the CXXC domain, and we have used DNA in canonical B-form for structure calculations.
The structure of the MLL CXXC domain in the complex with DNA is very similar to that of the free protein 26 (data not shown). The CXXC domain binds DNA by inserting in a wedge-like manner into the major groove with the protein perpendicular to the DNA axis (Fig. 1a) . The CXXC domain contacted a short 6-bp sequence of the DNA centered on the CpG motif. Notably, all of the base-specific contacts are limited to the central CpG dinucleotide and are therefore consistent with the binding data described above. The surface area buried in the protein-DNA interface is relatively small (~1,060 Å 2 ) compared to the 1,340-Å 2 average contact area observed for protein-DNA complexes 27 , consistent with the moderate affinity of this interaction. The elongated shape of the CXXC domain results in residues distributed throughout the entire domain making contacts with DNA. These contacts are abundant in the major groove and reach the phosphate backbone in the minor groove (Fig. 1) . The majority of the intermolecular interactions are mediated by the 1182-1188 loop, which forms the recognition element for the CpG motif. Several residues outside the 1182-1188 loop participated in electrostatic and hydrophobic interactions with the sugar-phosphate backbone, contributing to binding.
The identities of the residues involved in contacts with the DNA major groove agree well with a previous study using saturation transfer mapping to identify residues at the protein-DNA interface 26 . However, we additionally found interactions involving the protein a r t i c l e s a r t i c l e s (Arg1150, Ser1152 and Leu1197) and the DNA minor groove (see Fig. 1b ) not identified in the previous study. This was corroborated by the finding that mutating Arg1150 and Leu197 to alanine decreased binding by a factor of 5 and 4, respectively (Fig. 2) . We were unable to express the S1152A mutant in a soluble form, suggesting that it may contribute to protein stability or folding. We also mutated Met1200 to alanine, which gave rise to two weak NOEs to DNA. Notably, a moderate increase in DNA-binding affinity was observed which may indicate relief of a steric clash of Met1200 with DNA.
Structural basis for CpG recognition
The structure of the CXXC-DNA complex represents the first detailed insight into the molecular basis of recognition of CpG motifs by CXXC domains and explains the basis for discrimination between methylated and unmethylated DNA. Notably, recognition of the CpG motif involves a short 1182-1188 loop that mediates all base-specific contacts with DNA. Unlike the majority of protein-DNA complexes, these contacts are very limited and involve interactions with both side chains and the protein backbone. Specificity for CpG recognition is achieved by means of four intermolecular hydrogen bonds.
The key element discriminating CpG versus other dinucleotides is the recognition of the two N4-amine groups (in C118 and C106) by formation of hydrogen bonds with two protein-backbone oxygens (Lys1185 and Lys1186, respectively) ( Fig. 1) . In addition, the side chain of Lys1186 is in position to form a hydrogen bond with G119, and the side chain amide of Gln1187 forms hydrogen bonds with G107 ( Fig. 1d) . Close contacts between DNA bases and the protein backbone aided in discrimination between methylated and unmethylated cytosines. The H5 protons of C106 and C118 are in very close proximity to the backbone Hα of Gln1187 (2.3 ± 0.1 Å) and carbonyl of Ile1184 (2.3 ± 0.3 Å), respectively ( Fig. 1) . Methylation of either of these cytosines would result in a steric clash with the protein backbone, thus precluding binding of methylated DNA. In addition to base-specific contacts, there are numerous interactions involving protein side chains and the sugar-phosphate backbone of the DNA (Fig. 1b) . Electrostatic interactions with the DNA are mediated by the side chains of Arg1150, Arg1154, Lys1176, Lys1178, Lys1185, Lys1190, Arg1192 and Lys1193. In addition, Ile1184 contacts the hydrophobic part of the deoxyribose of G117. Notably, we also observed several weak NOEs involving the side 
Design of CXXC mutations to abrogate DNA binding
In order to probe the importance of protection of CpG motifs from methylation mediated by the CXXC domain, we developed mutations that specifically disrupted DNA binding without disruption of the protein fold. We selected three types of sites for mutagenesis: alanine substitutions for residues involved in electrostatic interactions with the DNA (Arg1154, Lys1185 and Lys1193); substitution for a residue, Gln1187 (Q1187A), involved in specific DNA contacts; and introduction of a repulsive interaction with the DNA backbone via a C1188D substitution (see Fig. 2a ). All of the expressed mutants were folded and had very similar heteronuclear single-quantum coherence (HSQC) spectra to the wild-type protein, indicating that the mutations did not cause any structural changes. The affinities of the mutants toward the DNA pal oligonucleotide were measured by NMR titration experiments (Fig. 2c,d) . The wild-type protein yielded a K d of 44 µM, in agreement with the ITC results for other oligonucleotides with a single CpG element (Supplementary Table 1 ). The mutations interfering with electrostatic interactions decreased the binding affinity by a factor of 9 to 15 (Fig. 2b) . A less pronounced effect (factor of six higher K d ) was observed for the Q1187A mutation, abrogating interaction between the glutamine side chain and the guanine base within the CpG motif. Our results are consistent with a previous qualitative assessment of DNA binding by CXXC mutants using EMSA 26 . To generate a mutant of the CXXC domain completely unable to bind DNA, we selected Cys1188, a residue that is located in close proximity to the DNA backbone and thus could be used to introduce a repulsive interaction. Although a C1188A mutation had no effect on DNA binding, the C1188D mutation led to the inability to detect any binding to DNA by NMR (Fig. 2d) .
MLL-AF9 C1188D increases methylation of Hoxa9 CpG island
To investigate the role of the CXXC domain in methylation protection, we introduced the C1188D mutation into MLL-AF9. For comparison, we also included the inert C1188A mutation which does not affect DNA binding. After stable transfection of MLL-AF9 C1188A or MLL-AF9 C1188D constructs into Mll-null mouse embryonic fibroblast (MEF) cells, we measured the methylation levels of CpG residues in the upstream region of the Hoxa9 locus. Genomic DNA samples underwent bisulfite treatment, and then nested PCR was performed and PCR products were sequenced. Methylation levels were determined as we described previously 20 . Western blotting showed that all MLL-AF9 point mutation constructs were expressed (Supplementary Fig. 1 ).
We have analyzed the Hoxa9-locus CpG-island methylation within cells expressing MLL-AF9 C1188A and found a level of nonmethylated CpGs consistent with what we previously showed regarding the effect of another MLL fusion, MLL-AF4, in a similar experiment 20 . In contrast, the level of CpG methylation in cells expressing MLL-AF9 C1188D was increased compared to MLL-AF9 C1188A (Fig. 3a) . Therefore, a point mutation in the CXXC domain which abrogates DNA binding also leads to substantial loss of Hoxa9 methylation protection by MLL-AF9. Our findings provide direct evidence that the CXXC domain is required for maintenance of CpG DNA in the nonmethylated state.
MLL-AF9 C1188D decreases levels of Hoxa9 and mir196b
The transforming potential of cells bearing MLL fusion proteins is correlated with high levels of expression of Hoxa9 (refs. 9,14) as well as of the microRNA mir196b (ref. 28) , which is within the Hoxa9 locus. We have demonstrated that cells expressing MLL-AF9 C1188D have increased methylation of the Hoxa9 CpG island compared to MLL-AF9 C1188A . This should lead to decreased levels of expression for Hoxa9 and mir196b. To test this, we introduced MLL-AF9 C1188A and MLL-AF9 C1188D into bone marrow progenitors via retroviral transduction and measured the levels of Hoxa9 and mir196b by RT-PCR. Bone marrow cells expressing MLL-AF9 C1188A , with normal DNA-binding activity, expressed significantly higher levels of Hoxa9 and mir196b than cells expressing the retroviral vector alone, as expected for MLL fusion proteins (Fig. 3b,c) . 
a r t i c l e s
In striking contrast, bone marrow cells expressing MLL-AF9 C1188D expressed Hoxa9 levels a factor of 30 lower and mir-196b a factor of 27 lower than MLL-AF9 C1188A cells, levels similar to or below those expressed by cells expressing empty vector (Fig. 3b,c) .
MLL-AF9 C1188D occupies Hoxa9 and increases H3K9 methylation
We examined the occupancy of MLL-AF9 mutants C1188A and C1188D at the Hoxa9 locus using ChIP. The occupancy of MLL-AF9 at this locus is not significantly affected by the introduction of the C1188D mutation (Fig. 3d) , which eliminates DNA binding by the CXXC domain. This is consistent with recent studies demonstrating a critical role for interaction with menin, a key MLL fusion interaction partner, in localization of MLL to target genes 29 . RNA polymerase II (Pol II) occupancy at the Hoxa9 locus showed a trend toward decreased binding with the C1188D mutation, although this trend did not reach statistical significance. In contrast, the level of trimethylated H3K9 increases significantly with introduction of the C1188D mutation. As this is a mark of repressive chromatin, this increase correlates very well with the decreased Hoxa9 expression seen by RT-PCR.
CXXC mutations abrogate transforming potential of MLL-AF9
Loss of protection of Hoxa9 CpG islands from methylation and subsequent downregulation of Hoxa9 and mir-196b expression should have a pronounced impact on the transforming properties of leukemogenic MLL fusion proteins. To assess this, we introduced the mutations impairing DNA binding of the CXXC domain into MLL-AF9 and assessed their function in a colony formation assay 30 . Whereas normal mouse bone marrow progenitor cells can form colonies when plated in semisolid medium in vitro, these cells differentiate and cannot be serially re-plated. In contrast, if MLL fusions are introduced into bone marrow progenitors, the cells can be serially re-plated and become immortalized.
Bone marrow cells expressing MLL-AF9 showed high clonogenic activity as well as high proliferative capacity throughout 4 weeks of re-plating (Fig. 4a) . For example, after four platings almost 16% of the plated cells could each give rise to a colony, and the total cell numbers increased on average by 900-to 1,000-fold (Fig. 4a) . A similar transforming potential was observed for MLL-AF9 C1188A , which does not alter the DNA-binding affinity of the CXXC domain. Cells transduced with MLL-AF9 C1188A showed similar number of colonies to those transduced with MLL-AF9, and the colonies for both of these constructs were large and densely filled with cells and had a uniform round shape typical of progenitor or blast cells (Fig. 4b) . Cytospin and Wright-Giemsa staining of MLL-AF9-or MLL-AF9 C1188A -transduced cells after four platings revealed morphology expected for blasts rather than differentiated cells (Fig. 4b) . In contrast, MLL-AF9 C1188D lacks colony-forming ability (the C1188D mutant cells proliferated on average only 1.7-fold) and behaved similarly to the MSCVneo negative control (Fig. 4a) . These colonies rarely survived into the fourth week of the colony assay, and the surviving colonies were always very diffuse with small numbers of differentiated cells (Fig. 4b) .
Deletion of the CXXC domain, mutation of cysteines that participate in zinc coordination or mutation of the KFGG motif to AAAA all were shown previously to eliminate in vitro transformation by MLL-ENL 18 . However, it is difficult to assess the specific roles of these mutations because all of them disrupt the CXXC-domain fold 26 . It is known that the CXXC domain, in addition to DNA binding, also mediates protein-protein interactions with polycomb group proteins and histone deacetylases 19 ; therefore, a misfolded CXXC domain could potentially interfere with multiple functions. Here, we have identified the C1188D mutation in the CXXC domain which disrupts DNA binding specifically while maintaining the protein structure. Therefore, we can specifically attribute the DNA-binding capability of the CXXC domain as absolutely required for the transforming potential of MLL fusions.
We also assessed other mutations in the CXXC domain of MLL-AF9 that only partially decrease DNA-binding affinity. Notably, introduction of the R1154A, K1185A and Q1187A mutations into MLL-AF9 resulted in greatly reduced colony-forming ability compared to MLL-AF9 (Fig. 4) . The number of colonies for these mutants in the final week of the assay varied and ranged from 0 to 300. However, all three mutants were vastly diminished in clonogenic activity compared to the average of 1,500 colonies demonstrated by MLL-AF9 at the last re-plating time assessed. The reduced colonyforming ability and proliferative capacity of the MLL-AF9 variants shows a good correlation with the DNA-binding affinities of the CXXC mutants (Fig. 4a) . Mice expressing MLL-AF9 C1188D do not develop leukemia Finally, to evaluate whether the disruption of the CXXC-DNA interaction will affect leukemogenic transformation in vivo, we have introduced MLL-AF9 C1188A and MLL-AF9 C1188D into mice. The c-Kit (CD117)-positive bone marrow progenitor cells retrovirally transduced with MSCV-MLL-AF9 containing point mutations C1188A or C1188D or with MSCVneo negative control were transplanted into lethally irradiated C57Bl/6 mice. All mice expressing the C1188A mutant developed AML within 46 d (n = 8), as expected for MLL-AF9-infected mice 31, 32 (Fig. 5a) . At the time of killing due to leukemia-related morbidity, the MLL-AF9 C1188A mice had elevated white-blood-cell counts (range: 12.28 K µl -1 to 4,680 K µl -1 ) (Fig. 5b) , pale femurs, and enlarged spleens and livers with infiltrating leukemia cells (see Supplementary Fig. 2) . Peripheral blood cells expressed surface markers typical of MLL-AF9 myeloid leukemia. They were positive for c-Kit, CD11b and Gr-1, but negative for B220 and CD3. The mice infected with control MSCVneo (n = 5) did not develop leukemia. Notably, no mice (n = 9) transduced with MLL-AF9 C1188D developed leukemia up to 200 d after transplant, when they were sacrificed (Fig. 5a ). This shows that DNA binding by the CXXC domain in MLL-AF9 is required to induce leukemia in vivo.
DISCUSSION
To shed light on the molecular mechanism of MLL fusions, we have solved the structure of the CXXC domain in complex with CpG DNA. This provided the first detailed structural account of how the CXXC domain discriminates between methylated and nonmethylated DNA. Subsequently, we have used the structure of the CXXC-DNA complex to design point mutations in the CXXC domain that impair DNA binding without disrupting the fold of the domain. Introduction of these mutations into MLL-AF9 showed that the DNA-binding function of the CXXC domain is indispensable for transformation of bone marrow progenitor cells and for leukemogenic transformation in mice. Consistent with this, cells expressing the non-oncogenic MLL-AF9 C1188D variant with no CpG DNA binding have significantly increased CpG methylation of a specific region of the Hoxa9 locus, increased H3K9 methylation and decreased expression of Hoxa9 locus transcripts, critical mediators of MLL fusion leukemia. To date, the role of the CXXC domain in leukemogenic transformation has only been assessed using in vitro colony-forming ability 18, 33 . In this work, for the first time to our knowledge, we have demonstrated that DNA binding by the CXXC domain is critically important for MLL-AF9 leukemogenesis in vivo. On the basis of our studies, we are proposing a novel mechanistic role for the CXXC domain in maintaining expression of Hoxa9 by MLL fusion proteins. It is well established that MLL fusions are localized to the Hoxa9 locus 20, 34 . Recent studies indicate that interactions with menin and LEDGF are critical for this localization 16, 29 . Not surprisingly, based on the modest affinity of the CXXC domain for DNA, we have shown by ChIP that the CXXC domain has little to no role in localization to Hoxa9. Rather, our data clearly demonstrate that when the MLL fusion is localized to a specific site, the CXXC domain functions to maintain CpG motifs in the nonmethylated state that is essential for maintenance of appropriate epigenetic marks and continued transcription. Thus, upon localization to the Hoxa9 locus, the presence of the CXXC domain is critical for maintenance of the high level of transcription of Hoxa9 and mir196b seen in MLL leukemias (Fig. 6a) . Indeed, we have shown that the C1188D mutation, which abolishes DNA binding by the CXXC domain, results in increased methylation of Hoxa9 and an increase in histone H3K9 methylation, leading to downregulation of Hoxa9 and mir196b transcription (Fig. 6b) . As a consequence, mutants of MLL-AF9 with impaired CXXC DNA binding fail to induce transformation or leukemia in mice.
Patients with acute leukemias harboring MLL translocations have poor prognosis with current therapies and a very low survival rate 35 . Therefore, there is a pressing need to develop novel approaches for treatment of MLL leukemias. Notably, our results provide support for the idea that the interaction of the CXXC domain with DNA may constitute a useful drug target for MLL-related leukemias. Because the CXXC domain is preserved in all MLL translocations, inhibition of the CXXC-DNA interaction would be a general approach to reverse the oncogenic potential of MLL fusion proteins. Inhibition of the interaction of transcription factors with DNA is commonly considered a challenging task because of the typically very high DNA-binding affinities of transcription factors (low nanomolar range). However, the CXXC domain binds DNA much more weakly (micromolar affinity), and our experiments demonstrate that even a factor of six decrease in DNA-binding affinity of the CXXC domain has a pronounced effect on the transforming potential of MLL fusions.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Coordinates for the CXXC-DNA complex have been deposited with the accession code 2KKF.
